DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

DE

477.85

+1.78%↑

FDX

241.56

-0.91%↓

PAYX

154.48

+0.25%↑

CPRT

57.2

+1.13%↑

HEICA

212.51

+0.9%↑

Search

Ocugen Inc

Suletud

0.64 -8.57

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.62

Max

0.71

Põhinäitajad

By Trading Economics

Sissetulek

-910K

-14M

Müük

-372K

764K

Aktsiakasum

-0.05

Kasumimarginaal

-1,816.754

Töötajad

95

EBITDA

-603K

-13M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+839.44% upside

Turustatistika

By TradingEconomics

Turukapital

57M

233M

Eelmine avamishind

9.21

Eelmine sulgemishind

0.64

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

Ocugen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. apr 2024, 14:32 UTC

Suurimad hinnamuutused turgudel

Ocugen Gets FDA Clearance for IND Amendment for OCU400

Võrdlus sarnastega

Hinnamuutus

Ocugen Inc Prognoos

Hinnasiht

By TipRanks

839.44% tõus

12 kuu keskmine prognoos

Keskmine 6.67 USD  839.44%

Kõrge 8 USD

Madal 4 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Ocugen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

0.5163 / 0.7995Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.